Swixx BioPharma AG, a global trade platform dedicated to worldwide access to innovative medications, has announced its strategic expansion into Latin America by signing an agreement to acquire Biopas S.A. This significant acquisition, involving the entirety of the stock capital of Pharma Consulting Group S.A., positions Swixx BioPharma to become a compelling, multi-continental partner for biopharmaceutical companies. With this merger, Swixx will effectively enter new markets including Argentina, Brazil, Chile, Colombia, and Mexico. The transaction, expected to close by June-July 2024 following regulatory approvals, is set to bolster Swixx’s market presence with $220 million in additional revenue and over 300 new employees specializing in areas such as neurology, oncology, immunology, gastroenterology, and rare diseases. The management team of Biopas will remain integral to operations in Latin America, maintaining the brand name under the expanded Swixx BioPharma umbrella. This move follows Swixx BioPharma’s previous market entry in the Middle East in September 2023, solidifying its position as a leading trade platform for the biopharma industry across multiple continents. The financials project Swixx BioPharma to achieve revenue exceeding one billion euros in 2024.

Pharmaceuticals, Biotechnology, Healthcare,Switzerland, Colombia, Latin America